Company intelligence / Profile preview
Qlaris Bio
Wellesley Hills, Massachusetts, United Statesqlaris.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
QLS‑111, the lead asset, has demonstrated positive topline results in two Phase II trials for primary open-angle glaucoma and ocular hypertension. The drug met all primary and secondary endpoints; when added to latanoprost it achieved up to a 3.6 mmHg greater reduction in intraocular pressure compared to latanoprost alone.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules (ATP-sensitive potassium channel modulators)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Mayo Clinic Ventures (technology origin/collaboration)
Beyond the preview
Go deeper on Qlaris Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qlaris Bio.